Key Benefits of PCR-based mRNA manufacturing for clinical development

by Dr. Julian Mochayedi and Eike Joest | September 1, 2023


mRNA Webinar Series:

mRNA technology offers many opportunities but the development and manufacturing of mRNA-based vaccines and therapeutics present a number of challenges. Learn more about the opportunities of the mRNA technology and how to overcome drug development and manufacturing challenges to bring your mRNA-based therapies to market in this first webinar.

In this webinar, you will learn:

  • Which key parameters impact mRNA manufacturing speed, capacities as well as quality
  • Understand the benefits of our flexible GMP mRNA manufacturing platform for clinical and commercial mRNA demands
  • How our innovative PCR-based process can accelerate your mRNA development and manufacturing program
  • mRNA CDMO Services as part of our highly connected network to ensure speed, scalability, quality and flexibility for mRNA, lipid, LNP formulation and Fill & Finish

Detailed description: 

To unlock the potential of your mRNA therapies and accelerate your mRNA development and manufacturing program, discover the benefits of our novel PCR-based mRNA drug substance manufacturing process. With this innovative and flexible process, we can provide mRNA at all scales and qualities for all stages of a mRNA program life cycle, from pre-clinical to commercial.

Learn about our truly integrated mRNA-LNP CDMO offering, and how we can support you as the single-source partner along all critical steps from mRNA drug substance manufacturing, through lipids and lipid nanoparticle (LNPs) to fill & finish of the final drug product.

To view this webinar, click here.

Strategic Marketing Manager for mRNA Solutions

Julian is the strategic marketing manager for mRNA solutions and responsible for the strategy development and positioning of the mRNA CDMO offering based on the acquisition of AmpTec GmbH, a leading mRNA CDMO.
Prior to joining

Merck KGaA in Darmstadt, Germany

, he gained experience in translational research with profound expertise in the areas of novel modalities and in vivo gene editing. Julian holds a M.Sc. in bioprocess development and a Ph.D. in translational immunology from Heidelberg University.

Principal Scientist for mRNA Innovation

Eike is Principal Scientist for innovations and technologies in mRNA service offering. He was responsible for development of the upscaled mRNA manufacturing process and implementation of AmpTec™ technologies in R&D.
Before joining

Merck KGaA in Darmstadt, Germany

, he demonstrated broad technical expertise in synthetic biology and molecular biology by publishing in several peer-reviewed journals. Eike holds a M.Sc. with distinction in Biochemistry from Wuerzburg University and a summa cum laude Ph.D. in cellular Biochemistry from Frankfurt University.

Related Posts

Biopharmaceutical Manufacturing: An Evolving Industry

Chemical Engineering Magazine has published its second article of the biopharmaceutical manufacturing series, written by Biomanufacturing Engineer, David…

Webinar: “See How Single-Use Technologies Are Well-suited for the Manufacture of mRNA”

Single-use technologies are well-suited for the manufacture of mRNA. Not only do they offer increased flexibility, they can…

What to consider for a modular facility with closed processing

The biopharmaceutical industry trends towards new product classes and smaller batch sizes drives even a greater need for…

Market Watch & Perspectives on Vaccines Manufacturing in APAC

recently commissioned Economist Intelligence Clearstate, a division of The Economist, to conduct a study on the future of…

Scroll to Top